Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has been described to markedly improve patient survival. However, reports describing the antitumor therapeutic efficacy and safety of ICIs in patients with autoantibodies are scarce. METHODS: This study examined the efficacy and feasibility of IC...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Shinomiya, Shun, Akagami, Tomoe, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2021
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8005657/
https://ncbi.nlm.nih.gov/pubmed/33791204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.610952
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires